Skip to content

Iovance Biotherapeutics, Inc. IOVA Intangible Amortization

Intangible Amortization at other companies

Danaher logo
DanaherDHR
$434M+5.9%

Other financials

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation

See full
Market cap$1.98B+32.4%
Enterprise value$1.83B+33.2%
P/S6.9×-0.1×

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s intangible amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s intangible amortization?
Iovance Biotherapeutics, Inc. (IOVA) reported intangible amortization of $5.72M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s intangible amortization changed year-over-year?
Iovance Biotherapeutics, Inc.'s intangible amortization increased by 4.0% year-over-year, from $5.5M to $5.72M.
What does intangible amortization mean?
Non-cash amortization of intangible assets (patents, customer relationships, technology) acquired through M&A or purchases.